Clinical Scorecard: Evaluating the Diagnostic Potential of Gut Microbiota Analysis and Blood Biomarkers for Predicting Post-Stroke Infections in Acute Ischemic Stroke Patients

At a Glance

Key Highlights

• PSI occurred in 46.3% of AIS patients within 7 days post-admission, with pneumonia and urinary tract infections as common complications.
• Circulating biomarkers NMDAR antibodies, iFABP, LPS, RANKL, butyrate, and TMAO showed high diagnostic accuracy individually (AUCs ranging from 0.865 to 0.911).
• Combined multivariate models integrating gut microbiota profiles and circulating biomarkers significantly improved early prediction of PSI compared to single-domain approaches.

Guideline-Based Recommendations

Diagnosis

• Use circulating biomarkers including NMDAR antibodies, iFABP, LPS, RANKL, butyrate, and TMAO to assess PSI risk in AIS patients.
• Incorporate gut microbiota profiling focusing on abundance of pathogenic taxa (Escherichia coli, Salmonella enterica) and depletion of SCFA-producing commensals (Faecalibacterium prausnitzii, Roseburia intestinalis) for enhanced diagnostic accuracy.
• Apply combined biomarker and microbiota models to improve sensitivity and specificity for early PSI detection.

Management

• Implement early risk stratification for PSI using integrated biomarker–microbiota models to guide preventive and therapeutic interventions.
• Monitor and potentially modulate gut microbiota composition to reduce PSI risk, considering the role of SCFA-producing bacteria in mucosal integrity and immune modulation.

Monitoring & Follow-up

• Regularly assess circulating biomarker levels (NMDAR, iFABP, LPS, RANKL, butyrate, TMAO) during the acute post-stroke period to detect early signs of infection.
• Monitor clinical signs of infection alongside biomarker and microbiota profiles to improve diagnostic confidence.

Risks

• Recognize that traditional inflammatory markers (CRP, PCT, WBC) may lack specificity due to confounding post-stroke systemic inflammation.
• Be aware of potential bacterial translocation and endotoxemia indicated by elevated LPS and iFABP levels, which may worsen neurological outcomes.

Patient & Prescribing Data

Acute ischemic stroke patients admitted within 24 hours of symptom onset without pre-existing infections or immunosuppressive conditions.

Early identification of PSI risk via combined biomarker and microbiota analysis may enable timely preventive strategies, potentially reducing infection-related morbidity and mortality.

Clinical Best Practices

• Integrate gut microbiota profiling with circulating biomarker assessment for comprehensive PSI risk evaluation in AIS patients.
• Focus on biomarkers reflecting distinct pathophysiological pathways: neuroimmune activation (NMDAR), intestinal barrier injury (iFABP), endotoxemia (LPS), inflammatory signaling (RANKL), and microbial metabolites (butyrate, TMAO).
• Use multivariate logistic regression models combining microbiota and biomarker data to enhance diagnostic accuracy beyond single markers.
• Exclude patients with recent antibiotic or probiotic use to avoid confounding microbiota analysis.
• Consider the role of SCFA-producing commensals in maintaining mucosal integrity and immune homeostasis when interpreting microbiota data.

References

• Stroke-associated pneumonia and inflammatory biomarkers
• Gut microbiota and post-stroke infection risk
• Microbial dysbiosis predicting stroke-associated pneumonia
• Endotoxemia and neurological outcomes after stroke
• Intestinal fatty acid-binding protein as a marker of mucosal injury
• TMAO and stroke severity and outcomes